RxDoctor Payments DataLook up a doctor →

Michael Hull, DO

Pulmonary Disease · Edmond, OKNPI 1396891743

Payments from drug & device makers

$742,574in general payments, 2019–2025

Across 281 payments — averaging $2642.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cipla USA Inc.$662K
  • GSK$68K
  • Novartis$8K
  • Boehringer Ingelheim$556
  • Actelion Pharmaceuticals US, Inc.$508
  • AstraZeneca$381
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$637,27599%
  • Food & beverage$4,1501%
  • Education$1380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$742,574 in reported general payments places this provider in the 95th percentile of 133 pulmonary disease providers in Oklahoma.

See all pulmonary disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$179,412
Medicare patients
618
Services billed
1,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter416$438,545
GlassiaAlpha-1-Proteinase Inhibitor13$328,699
OfevNintedanib Esylate26$325,435
Breztri AerosphereBudesonide/Glycopyr/Formoterol232$223,528
ZemairaAlpha-1-Proteinase Inhibitor13$212,639
Fasenra PenBenralizumab15$96,065
Breo ElliptaFluticasone/Vilanterol159$93,967
Stiolto RespimatTiotropium Br/Olodaterol Hcl87$80,984
XolairOmalizumab12$67,205
Spiriva RespimatTiotropium Bromide73$61,103
Combivent RespimatIpratropium/Albuterol Sulfate46$33,004
EliquisApixaban31$31,971
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$24,352
SymbicortBudesonide/Formoterol Fumarate46$19,138
Albuterol Sulfate HfaAlbuterol Sulfate283$11,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$68,358$556,864608 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$556$500,525232 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$53$328,69913 claims
AstraZenecaBreztri Aerosphere, Symbicort, Airsupra$381$248,594291 claims
CSL BehringZemaira$150$212,63913 claims
PfizerEliquis$73$31,97131 claims
MerckDulera$72$8,10514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 pulmonary disease providers in Oklahoma.

Other pulmonary disease in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →